Immunotherapy boost may improve outcomes in returning throat cancer

NCT ID NCT03907826

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether adding an immunotherapy drug (PD-1 antibody) to standard chemoradiotherapy helps people with recurrent nasopharyngeal carcinoma live longer. About 212 participants whose cancer has returned after prior treatment and cannot be surgically removed will be randomly assigned to receive either the combination or chemoradiotherapy alone. The study measures overall survival, cancer progression, side effects, and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT NASOPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT NASOPHARYNGEAL CARCINOMA

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
NOT_YET_RECRUITING

Shanghai, China
Fujian Province Cancer Hospital
NOT_YET_RECRUITING

Fuzhou, China
Guizhou Cancer Hospital
RECRUITING

Guiyang, China
Jiangxi Cancer Hospital
NOT_YET_RECRUITING

Nanchang, China
Peking University Third Hospital
NOT_YET_RECRUITING

Beijing, China
Sichuan Cancer Hospital
NOT_YET_RECRUITING

Chengdu, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangxi Medical University
RECRUITING

Nanning, China
The First Affiliated Hospital of Xiamen University
NOT_YET_RECRUITING

Xiamen, China
Xijing Hospital
RECRUITING

Xi'an, China
Zhejiang Cancer Hospital
NOT_YET_RECRUITING

Hangzhou, China
Zhongnan Hospital of Wuhan University
RECRUITING

Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.